Drugs / Bifidobacterium breve PRL2020
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06850714 | Feb → Jun 2025 overdue | poisoning | Liaquat University of Medical & Health Sciences | Not yet recruiting | No outcome recorded |
| — | NCT05840588 | Nov 2023 → Mar 2025 | bacterial infectious disease | Liaquat University of Medical & Health Sciences | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bifidobacterium breve PRL2020 | “Probiotic Bifidobacterium breve PRL2020 (Brevicillin®) at a dose of 20 billion CFU per day (one stick in the morning and one in the evening).” NCT06850714 ↗1“Probiotic Bifidobacterium breve PRL2020 (Brevicillin®) treatment” NCT05840588 ↗ |
| Known as | Brevicillin | “Probiotic Bifidobacterium breve PRL2020 (Brevicillin®) treatment” NCT05840588 ↗ |
| Modality | Other / unclassified | “probiotic Bifidobacterium breve PRL2020 (Brevicillin®)” NCT05840588 ↗ |